Japan ' s Shionogi eyes early 2025 for U.S. release of COVID pill
OSAKA -- Japanese drugmaker Shionogi expects to be able to sell its Xocova COVID-19 treatment in the U.S. in early 2025, part of a focus on overseas sales as public funding for coronavirus medications in Japan ends this month. If the review by the U.S. Food and Drug Administration goes smoothly…#osaka #shionogi #xocovacovid19 #isaoteshirogi
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Coronavirus | COVID-19 | Eyes | Food and Drug Administration (FDA) | Funding | Health | Japan Health